Home » Health Resources » Clinical Trials

Clinical Trials

Beaumont Health System, with three hospitals in the northern Detroit suburbs serving southern Michigan and beyond, is a highly productive contributor to clinical trials across the nation. The Beaumont Research Institute, established by the hospital’s Board of Trustees in 1966, strengthens Beaumont's ability to conduct medical research and to provide a research training experience for the medical staff and participants in graduate medical education programs.

PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ULARITIDE (URODILATIN) INTRAVENOUS INFUSION IN PATIENTS SUFFERING FROM ACUTE DECOMPENSATED HEART FAILURE (TRUE-AHF) - Protocol Number ULA01

Status: open and enrolling

Approval Date: 11/1/2012

The purpose of this study is to evaluate the efficacy and safety of a continuous intravenous (IV) ularitide infusion on the clinical status and outcome of patients with acute decompensated heart failure (ADHF). ADHF is a condition in which the heart has lost the ability to pump enough blood. Ularitide is an investigational drug meaning that it has not yet been approved by the FDA for use.


Unpublished
n/a

Unpublished
n/a

A RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY COMPARING THE EFFECT OF ONCE-WEEKLY DULAGLUTIDE WITH ONCE-DAILY LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES (AWARD-6: ASSESSMENT OF WEEKLY ADMINISTRATION OF LY2189265 IN DIABETES-6)

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes (AWARD-6)

Status: open and enrolling

Approval Date: 8/23/2012

The purpose of the study is to assess the benefits and risks of once-weekly dulaglutide compared to once-daily liraglutide in participants with type 2 diabetes who have inadequate glycemic control on metformin.


A RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY COMPARING THE EFFECT OF ONCE-WEEKLY DULAGLUTIDE WITH ONCE-DAILY LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES (AWARD-6: ASSESSMENT OF WEEKLY ADMINISTRATION OF LY2189265 IN DIABETES-6)

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes (AWARD-6)

Status: open and enrolling

Approval Date: 8/23/2012

The purpose of the study is to assess the benefits and risks of once-weekly dulaglutide compared to once-daily liraglutide in participants with type 2 diabetes who have inadequate glycemic control on metformin.